Effect of Dapagliflozin on LV Remodeling Post AMI

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The overall hypothesis of the study is that Dapagliflozin will reduce left ventricular remodeling in patients who have had a myocardial infarction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Mexicano del Seguro Social
• Treatments: 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; Dapagliflozin

Criteria

Inclusion Criteria:

• Acute myocardial infarction treated within the 24 hours of beginning of symptoms

• Signed informed consent

• SBP > 90 mmHg

• Age >= 18 years

Exclusion Criteria:

• Glomerular Filtration Rate < 30 ml/min/1.73 m2.

• Pregnant or lactating woman

• Cancer or life-threatening condition

• Use of continuous parental inotropic agents

• Psychiatric disease incompatible with being in study.

• Any contraindication to MRI procedures.

• Any other medical or physical condition considered to be inappropriate by a study physician

• Scheduled for a PCI or CABG within the next 6 months

• Hemodynamic unstability

• Currently on any SGLT2i

• One or more episodes of severe hypoglicemia

• Acute urinary or genital infection